Lixisenatide: difference between revisions
Diff·revision 7 → 8·20:31, 23 Jan 2025
Difference between revision 7 and revision 8 of Lixisenatide. 6 lines changed; the page grew by 634 bytes.
| Revision 7 — 17:24, 31 Dec 2024 MolarMassMaeve (talk) add CAS number, sourced 2,302 bytes ±0 | Revision 8 — 20:31, 23 Jan 2025 StyleSheetSybil (talk) rm duplicated pharmacokinetics — the same figures appear in the infobox 2,936 bytes +634 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = Lixisenatide | 2 | | name = Lixisenatide |
| + | 3 | | subtitle = Clinical data | |
| 3 | | Class = [[GLP-1 receptor agonist]] | 4 | | Class = [[GLP-1 receptor agonist]] |
| 4 | | Origin = Exendin-4 derivative | 5 | | Origin = Exendin-4 derivative |
| ⋮ | ⋮ | ||
| 19 | 20 | ||
| 20 | Non-attenuating emptying delay is a genuine pharmacological difference from the weekly agents and is the reason short-acting agents retain a niche where postprandial excursions are the problem.{{r|drucker2018}} | 21 | Non-attenuating emptying delay is a genuine pharmacological difference from the weekly agents and is the reason short-acting agents retain a niche where postprandial excursions are the problem.{{r|drucker2018}} |
| + | 22 | ||
| + | 23 | == ELIXA and its significance == | |
| + | 24 | ELIXA randomised 6,068 participants with type 2 diabetes within 180 days of an acute coronary syndrome, and reported a hazard ratio of 1.02 for the primary composite — a clearly neutral result establishing non-inferiority without any suggestion of benefit.{{r|pfeffer2015}} | |
| + | 25 | ||
| + | 26 | Set beside [[LEADER trial|LEADER]] and [[SELECT trial|SELECT]], which were positive, and the exenatide outcome trial, which was neutral, the pattern within the class is mixed. Whether the differences reflect molecule, exposure profile, population or trial size is unresolved.{{r|drucker2018}} | |
| 21 | 27 | ||
| 22 | == References == | 28 | == References == |